FOLR1 and ovarian carcinoma: With the recognition of the importance of mitochondrial C1 catabolism from serine to the malignant phenotype, including ovarian cancer, an exciting new generation of investigational agents which target this pathway (e.g., SHIN2 and AGF347) is being developed [150,151,153,155], some of which are transported by FRα and the PCFT and potently inhibit EOC cells [156].